The metabolite upregulated CXCL3 expression by activating the JAK2/STAT3 signaling pathway, thereby promoting the infiltration of PMN-MDSCs in TME and inhibiting anti-tumor immune function of CD8+ T-cells. This evidence concerns the gene CXCL3 and neoplasm.